Literature DB >> 18176567

Transcription factor EBF restricts alternative lineage options and promotes B cell fate commitment independently of Pax5.

Jagan M R Pongubala1, Daniel L Northrup, David W Lancki, Kay L Medina, Thomas Treiber, Eric Bertolino, Matthew Thomas, Rudolf Grosschedl, David Allman, Harinder Singh.   

Abstract

Alternative lineage restriction and B cell fate commitment require the transcription factor Pax5, but the function of early B cell factor (EBF) in these processes remains mostly unexplored. Here we show that in the absence of EBF, 'expandable' and clonal lymphoid progenitor cells retained considerable myeloid potential. Conversely, ectopic expression of EBF in multipotential progenitor cells directed B cell generation at the expense of myeloid cell fates. EBF induced Pax5 and antagonized expression of genes encoding the transcription factors C/EBPalpha, PU.1 and Id2. Notably, sustained expression of EBF in Pax5-/- hematopoietic progenitor cells was sufficient to block their myeloid and T lineage potential in vivo. Furthermore, in Pax5-/- pro-B cells, higher EBF expression repressed alternative lineage genes. Thus, EBF can restrict alternative lineage 'choice' and promote commitment to the B cell fate independently of Pax5.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18176567     DOI: 10.1038/ni1555

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  110 in total

1.  Control of B cell development by the histone H2A deubiquitinase MYSM1.

Authors:  Xiao-Xia Jiang; Quan Nguyen; YuChia Chou; Tao Wang; Vijayalakshmi Nandakumar; Peter Yates; Lindsey Jones; Lifeng Wang; Haejung Won; Hye-Ra Lee; Jae U Jung; Markus Müschen; Xue F Huang; Si-Yi Chen
Journal:  Immunity       Date:  2011-12-08       Impact factor: 31.745

2.  The role of transcription factors in the guidance of granulopoiesis.

Authors:  Katja Fiedler; Cornelia Brunner
Journal:  Am J Blood Res       Date:  2012-01-01

3.  Transcription factor Ebf1 regulates differentiation stage-specific signaling, proliferation, and survival of B cells.

Authors:  Ildiko Györy; Sören Boller; Robert Nechanitzky; Elizabeth Mandel; Sebastian Pott; Edison Liu; Rudolf Grosschedl
Journal:  Genes Dev       Date:  2012-03-19       Impact factor: 11.361

4.  Repression of Id2 expression by Gfi-1 is required for B-cell and myeloid development.

Authors:  Huajie Li; Ming Ji; Kimberly D Klarmann; Jonathan R Keller
Journal:  Blood       Date:  2010-05-07       Impact factor: 22.113

5.  Ebf1 heterozygosity results in increased DNA damage in pro-B cells and their synergistic transformation by Pax5 haploinsufficiency.

Authors:  Mahadesh A J Prasad; Jonas Ungerbäck; Josefine Åhsberg; Rajesh Somasundaram; Tobias Strid; Malin Larsson; Robert Månsson; Ayla De Paepe; Henrik Lilljebjörn; Thoas Fioretos; James Hagman; Mikael Sigvardsson
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

6.  Altered metabolism and lipodystrophy in the early B-cell factor 1-deficient mouse.

Authors:  Jackie A Fretz; Tracy Nelson; Yougen Xi; Douglas J Adams; Clifford J Rosen; Mark C Horowitz
Journal:  Endocrinology       Date:  2010-02-19       Impact factor: 4.736

7.  Structure of an Ebf1:DNA complex reveals unusual DNA recognition and structural homology with Rel proteins.

Authors:  Nora Treiber; Thomas Treiber; Georg Zocher; Rudolf Grosschedl
Journal:  Genes Dev       Date:  2010-09-28       Impact factor: 11.361

Review 8.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

Review 9.  Transcriptional regulation of early B cell development.

Authors:  Daniel L Northrup; David Allman
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

10.  IL-7 specifies B cell fate at the common lymphoid progenitor to pre-proB transition stage by maintaining early B cell factor expression.

Authors:  Kazu Kikuchi; Hirotake Kasai; Akiko Watanabe; Anne Y Lai; Motonari Kondo
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.